Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade I Neuroendocrine Carcinoma”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Early research (Phase 1)Study completedNCT03879694
What this trial is testing

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Who this might be right for
Lung Atypical Carcinoid TumorLung Typical Carcinoid TumorMetastatic Pancreatic Neuroendocrine Tumor
Roswell Park Cancer Institute 19
Early research (Phase 1)Active Not RecruitingNCT04616248
What this trial is testing

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8+10 more
University of Southern California 14
Not applicableStudy completedNCT03616431
What this trial is testing

Pancreatic Cancer Dietary Assessment Study

Who this might be right for
Pancreatic NeoplasmPancreas AdenocarcinomaWell-Differentiated Neuroendocrine Carcinoma+1 more
The Christie NHS Foundation Trust 112
Testing effectiveness (Phase 2)Study completedNCT00445965
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+7 more
Memorial Sloan Kettering Cancer Center 78
Not applicableLooking for participantsNCT04464122
What this trial is testing

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1+2 more
University of Roma La Sapienza 60
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Looking for participantsNCT07114939
What this trial is testing

FTT PET/CT in Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Carcinoma MetastaticPancreatic Tumors
Abramson Cancer Center at Penn Medicine 12
Testing effectiveness (Phase 2)Looking for participantsNCT07357623
What this trial is testing

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

Who this might be right for
Pulmonary Neuroendocrine Tumor
Shanghai Chest Hospital 96
Large-scale testing (Phase 3)Looking for participantsNCT06855095
What this trial is testing

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2+1 more
The Netherlands Cancer Institute 39
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03728361
What this trial is testing

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Who this might be right for
Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine Carcinoma+9 more
Dwight Owen 55
Testing effectiveness (Phase 2)Looking for participantsNCT07115043
What this trial is testing

Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+6 more
AstraZeneca 60
Very early researchActive Not RecruitingNCT05111509
What this trial is testing

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Who this might be right for
Neuroendocrine Tumor Grade 2Neuroendocrine Tumor Grade 1
Yusuf Menda 20
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802174
What this trial is testing

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Who this might be right for
SCLCSmall Cell CancerAdvanced Solid Tumor+1 more
National Cancer Institute (NCI) 37
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)Looking for participantsNCT06395402
What this trial is testing

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2
University of Iowa 120
Load More Results
40